Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (688505) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (688505) has a cash flow conversion efficiency ratio of 0.019x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥43.77 Million ≈ $6.41 Million USD) by net assets (CN¥2.26 Billion ≈ $330.53 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2006–2024)
This chart illustrates how Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Shanghai Fudan-Zhangjiang Bio-Pharmaceut total liabilities for a breakdown of total debt and financial obligations.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zhongyeda Electric Co Ltd
SHE:002441
|
-0.038x |
|
Yan Tai Shuang Ta Food Co Ltd
SHE:002481
|
0.126x |
|
Heritage Insurance Hldgs Inc
NYSE:HRTG
|
0.284x |
|
MCEWEN MINING INC.
F:US8
|
N/A |
|
Yieh Phui Enterprise Co Ltd
TW:2023
|
0.038x |
|
Porch Group Inc
NASDAQ:PRCH
|
0.054x |
|
Guangdong Greenway Technology Co Ltd
SHG:688345
|
0.199x |
|
Nuh Cimento Sanayi AS
IS:NUHCM
|
0.012x |
Annual Cash Flow Conversion Efficiency for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (2006–2024)
The table below shows the annual cash flow conversion efficiency of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd from 2006 to 2024. For the full company profile with market capitalisation and key ratios, see Shanghai Fudan-Zhangjiang Bio-Pharmaceut (688505) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥2.31 Billion ≈ $337.33 Million |
CN¥-14.77 Million ≈ $-2.16 Million |
-0.006x | -121.28% |
| 2023-12-31 | CN¥2.36 Billion ≈ $345.13 Million |
CN¥71.02 Million ≈ $10.39 Million |
0.030x | -58.95% |
| 2022-12-31 | CN¥2.25 Billion ≈ $329.69 Million |
CN¥165.27 Million ≈ $24.18 Million |
0.073x | -40.27% |
| 2021-12-31 | CN¥2.19 Billion ≈ $320.41 Million |
CN¥268.90 Million ≈ $39.35 Million |
0.123x | +118.28% |
| 2020-12-31 | CN¥2.01 Billion ≈ $293.91 Million |
CN¥113.00 Million ≈ $16.54 Million |
0.056x | -80.50% |
| 2019-12-31 | CN¥933.15 Million ≈ $136.55 Million |
CN¥269.23 Million ≈ $39.40 Million |
0.289x | +64.76% |
| 2018-12-31 | CN¥993.28 Million ≈ $145.35 Million |
CN¥173.94 Million ≈ $25.45 Million |
0.175x | +265.92% |
| 2017-12-31 | CN¥892.48 Million ≈ $130.60 Million |
CN¥42.71 Million ≈ $6.25 Million |
0.048x | -70.28% |
| 2016-12-31 | CN¥873.05 Million ≈ $127.76 Million |
CN¥140.57 Million ≈ $20.57 Million |
0.161x | +28.05% |
| 2015-12-31 | CN¥765.84 Million ≈ $112.07 Million |
CN¥96.30 Million ≈ $14.09 Million |
0.126x | -3.74% |
| 2014-12-31 | CN¥676.42 Million ≈ $98.98 Million |
CN¥88.36 Million ≈ $12.93 Million |
0.131x | -17.35% |
| 2013-12-31 | CN¥565.92 Million ≈ $82.81 Million |
CN¥89.44 Million ≈ $13.09 Million |
0.158x | -62.69% |
| 2012-12-31 | CN¥260.11 Million ≈ $38.06 Million |
CN¥110.19 Million ≈ $16.12 Million |
0.424x | +71.76% |
| 2011-12-31 | CN¥201.07 Million ≈ $29.42 Million |
CN¥49.59 Million ≈ $7.26 Million |
0.247x | +685.36% |
| 2010-12-31 | CN¥168.71 Million ≈ $24.69 Million |
CN¥-7.11 Million ≈ $-1.04 Million |
-0.042x | -191.84% |
| 2009-12-31 | CN¥168.37 Million ≈ $24.64 Million |
CN¥7.72 Million ≈ $1.13 Million |
0.046x | +121.91% |
| 2008-12-31 | CN¥75.88 Million ≈ $11.10 Million |
CN¥-15.89 Million ≈ $-2.33 Million |
-0.209x | +13.44% |
| 2007-12-31 | CN¥71.04 Million ≈ $10.40 Million |
CN¥-17.18 Million ≈ $-2.51 Million |
-0.242x | -14.96% |
| 2006-12-31 | CN¥101.70 Million ≈ $14.88 Million |
CN¥-21.40 Million ≈ $-3.13 Million |
-0.210x | -- |
About Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., engages in the research, development, manufacture, and sale of bio-pharmaceutical products in the People's Republic of China. It offers genetic engineering platform drugs, including Trop2-SN38 ADC that is in Phase III clinical trials for Triple-negative breast cancer; CD30-DM1 antibody-drug conjugate (ADC), which have complected Phase I clini… Read more